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Abstract
Background: Pain is a frequent and inevitable factor affecting the quality of life among older people. Several
studies have highlighted the ineffectiveness of treating chronic pain among the aged population, and little is
known about the prevalence of analgesics administration among community-dwelling older adults. The objective
was to examine older adults’ prescription analgesic purchases in relation to SF-36 pain in a population-based
setting.
Methods: One thousand four hundred twenty community-dwelling citizens aged 62–86 years self-reported SF-36
bodily pain (pain intensity and pain-related interference) scores for the previous 4 weeks. The Social Insurance
Institution of Finland register data on analgesic purchases for 6 months prior to and 6 months after the
questionnaire data collection were considered. Special interest was focused on factors related to opioid purchases.
Results: Of all participants, 84% had purchased prescription analgesics during 1 year. NSAIDs were most frequently
purchased (77%), while 41% had purchased paracetamol, 32% opioids, 17% gabapentinoids, and 7% tricyclic
antidepressants. Age made no marked difference in purchasing prevalence. The number of morbidities was
independently associated with analgesic purchases in all subjects and metabolic syndrome also with opioid
purchases in subjects who had not reported any pain.
Discussion: Substantial NSAID and opioid purchases emerged. The importance of proper pain assessment and
individual deliberation in terms of analgesic contraindications and pain quality, as well as non-pharmacological pain
management, need to be highlighted in order to optimize older adults’ pain management.
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Background
Chronic pain is one of the leading conditions in later life
in terms of commonness and economic burden [1]. To
manage pain in older adults is known to be complex and
should always be based on proper assessment [2]. Des-
pite the commendable development of pain management
in recent years, the overall consensus highlights the
under-assessment, under-diagnosing, and under-
treatment/mistreatment of persistent pain in older indi-
viduals [3, 4].
Successful pain management is based on balancing the
benefits and harms of available drugs, on lifestyle inter-
ventions, and on treating the underlining cause as much
as possible [5]. Paracetamol has been recommended as
the first-line treatment for both acute and chronic pain
in older people, followed by non-steroidal anti-
inflammatory drugs (NSAIDs), but only if contraindica-
tions are not present [6, 7]. Pharmacological treatment
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modalities need to be combined with non-
pharmacological ones [6, 7]. Opioid administration may
be considered with moderate to severe cancer and non-
cancer pain, but never without precise individual delib-
eration and careful monitoring [7, 8]. Long-term opioid
administration for chronic non-cancer pain remains
controversial [9].
It has been discussed that NSAID use does not adhere
to clinical guidelines (e.g. long-term or pro re nata use
despite contraindications) in older adults [10–13], among
whom NSAIDs have been suggested to comprise a major
cause of drug-related morbidity [14]. NSAID-related pep-
tic ulcers, renal and cardiovascular adverse effects, and in-
creased mortality have been reported [14, 15]. Age-related
physiological changes, cognitive impairment (assessment,
adverse effects), multi-morbidity, and polypharmacy pose
major challenges to opioid administration [6, 16]. Adverse
effects are relatively frequent, with potentially severe con-
sequences [16]. An appropriate dose needs to be carefully
titrated and both the desired and adverse effects moni-
tored regularly [7, 8, 17].
Studies regarding analgesic administration among
community-dwelling older adults are scarce [10, 13, 18, 19].
It remains unclear how large a proportion of older adults
actually use analgesics and whether the medication consists
of NSAIDs or paracetamol, or of neuropathic drugs or opi-
oids [11, 20]. Multiple studies have suggested an increasing
trend in opioid prescribing over the recent years [21, 22],
but little is known about the actual opioid administration
among older adults [7, 19, 23].
The two main research questions of the current study
were as follows: 1) What are the purchasing prevalence
and profile of use of separate analgesics among older
community-dwelling citizens? 2) What is the relation-
ship between reported SF-36 pain and use of different
analgesics among older adults?
Based on the clinical point of view and previous stud-
ies that have presented an increasing trend in opioid
prescribing over the past two decades [22], opioid ad-
ministration was expected to emerge as relatively exten-
sive. To identify factors related to opioid use could
prove beneficial in terms of prevention. Therefore, the
third research question was: 3) Which factors are related
to opioid purchases?
Methods
The current research was a part of the Good Ageing in
Lahti Region (GOAL) study executed in the Päijät-Häme
Hospital District in Southern Finland [24]. The district
consists of both rural and urban areas, with approxi-
mately 220,000 inhabitants. The GOAL was a 10-year
follow-up cohort study (N = 2815) that introduced a
stratified (age, sex, 14 municipalities) random sample of
Finnish seniors born in 1926–30, 1936–40, and 1946–
50. At baseline (2002) and the three follow-up visits
(2005, 2008, and 2012), an extensive questionnaire was
filled out (overall health, attitudes, quality of life, etc.),
and blood samples and physical data were collected. The
design of the study has been described in more detail
elsewhere [24]. The present study focused on the 2012
data, which included the complete data regarding pre-
scribed pain medications. The total number of partici-
pants still attending at this point of the follow-up was
N = 1697. Subjects with insufficient data regarding re-
ported pain (N = 277) were excluded, and all statistical
analyses were therefore executed with 1420 subjects. In
2012, the participants were 62–-66, 72–76, and 82–86
years of age. Hospitalized and institutionalized older
adults did not participate in the study.
In Finland, patients are entitled to a reimbursement of
medication costs from the Social Insurance Institution
of Finland (SII). SII maintains a nationwide register of
all prescriptions and medication purchases, from which
the present data regarding analgesic purchases were re-
trieved. All pain medication purchases 6 months prior to
and 6 months after the questionnaire data collection
were considered. The presence vs absence of the drugs in the
participants’ purchasing history were retrieved. The exact num-
ber and dose were not retrievable. The temporal association be-
tween the pain assessment and analgesic purchases was not
retrievable. The analgesics considered were level 1 analgesics
(NSAIDs [Anatomical Therapeutic Chemical Classification Sys-
tem (ATC)] M01AE01, M01AE51 ibuprofen; M01AE03 keto-
profen; M01AH01, M01AH05, M01AH06 COX-2 selective
inhibitors; M01AC06 meloxicam; M01AE02, M01AE52 na-
proxen; M01AB05 diclofenac; M01AB01 indometin]; as well as
N02BE01, N02BE51 paracetamol) and level 2–3 analgesics
(N02AA01 morphine; N02AA03 hydromorphone; N02AA05
oxycodone; N02AA55 oxycodone-naloxone; N02AA59,
N02AJ06 codeine combinations; N02AB03 fentanyl; N02AE01
buprenorphine; N02AX02, N02AJ14 tramadol and tramadol
combinations), in addition to gabapentinoids (N03AX23 gaba-
pentin; N03AX16 pregabalin) and tricyclic antidepressants
(TCAs [N06AA09, N06CA01 amitriptyline; N06AA10 nortrip-
tyline]). Acetylsalicylic acid was excluded from the NSAIDs due
to its major use as an antithrombotic drug.
Data on the study participants’ pain, demographics, life
habits, morbidity, and symptoms were based on the GOAL
questionnaire. Regarding pain, the two-item Bodily Pain
section of the SF-36 questionnaire was used [25, 26]. The
participants indicated how severe pain they had experi-
enced during the previous 4 weeks (intensity; 100 = none,
80 = very mild, 60 =mild, 40 =moderate, 20 = severe, 0 =
very severe) and how much this pain had disrupted their
everyday work and activity (at home or outside of home)
during the previous 4 weeks (interference; 100 = not at all,
75 = a little bit, 50 =moderately, 25 = quite a bit, 0 = ex-
tremely). Bodily pain is presented herein as the mean of the
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pain intensity and interference scores. In the first analysis,
based on the bodily pain scores, the subjects were divided
into four pain groups (group I [0–45, moderate to very se-
vere pain intensity and interference], group II [47.5–70],
group III [77.5–90], group IV [100, no pain intensity and
interference at all]). The groups were established in order to
be able to combine pain intensity and pain-related interfer-
ence and to consider analgesic administration in relation to
the pain. The rationale for the four pain groups was to con-
sider separately the subjects who had reported high levels of
both pain intensity and pain interference (I) and those who
had reported none (IV). The rest were divided into two
groups (II–III) to equate the group sizes. In the second ana-
lysis, subjects were divided into two groups (opioid, non-
opioid) based on whether they had purchased opioids.
Household income was determined as the taxable
household income divided by the square root of the
number of people living in the household indexed to the
year 2017 [27]. Weekly alcohol consumption was mea-
sured with the 3-item AUDIT-C [28] instrument.
Leisure-time physical activity (LTPA) was determined as
activities lasting over 30 min that make the participant
sweat and pant at least to some degree (high [6–7 times
a week], moderate [3–5 times a week], low [1–2 times a
week or less, or not possible due to injury or illness])
[29]. The provided laboratory test data (fP-Glucose, fP-
Triglyceride, high-density lipoprotein [fP-HDL], esti-
mated glomerular filtration rate [eGFR, ml/min/1.73
m2], high-sensitivity C-reactive protein [S-hs-CRP],
rheumatoid factor, serum uric acid) and clinical mea-
surements (weight, height, blood pressure, waist circum-
ference) were considered. The morbidities examined
included cardiovascular, pulmonary, musculoskeletal,
psychiatric, and neurological diseases, as well as diabetes
mellitus type II and neoplasms. Prior to the regression
analyses, the sum of each participant’s diagnosed mor-
bidities was calculated. Metabolic syndrome (MetS) was
determined as the presence of three or more of the fol-
lowing components: 1) waist circumference ≥ 102 cm for
men and ≥ 88 cm for women; 2) fP-Triglycerides ≥1.7
mmol/L or treatment for dyslipidemia; 3) fP-HDL ≤1.03
mmol/L for men and ≤ 1.29 mmol/L for women, or
treatment for dyslipidemia; 4) systolic blood pressure ≥
130 mmHg or diastolic blood pressure ≥ 85mmHg, or
antihypertensive medication; and 5) fP-Glucose ≥5.6
mmol/L or the use of medication for hyperglycemia [30].
Also, the number of doctor’s appointments during the
previous 12 months was considered. For more details
about variables and coding, please contact the corre-
sponding author for the GOAL Codebook.
The descriptive statistics include means and SDs for
continuous variables and numbers and percentages for
categorical variables. Statistical significances for the hy-
pothesis of linearity across the SF-36 categories of bodily
pain were evaluated by using the Cochran–Armitage test
for trend and analysis of variance with an appropriate
contrast. Statistical comparisons between the opioid
usage groups were performed with the t-test, the Chi-
squared test, or the Fisher-Freeman-Halton test when
appropriate. In the case of a violation against the as-
sumptions (non-normality), a bootstrap-type test was ap-
plied. Multivariate logistic regression was employed to
investigate factors related to analgesic purchases. As pre-
dictors, the following were included: pain levels and
LTPA (as ordinal variables); sex, MetS, and smoking (as
dicotomous variables); and age, education years, Audit-C
and number of morbidities (as continuous variable). The
Hosmer-Lemeshow goodness-of-fit statistics were used
for the assessment of the final models. The normality of
variables was evaluated with the Shapiro-Wilk W test.
The Stata 15.1 statistical package by StataCorp LP (Col-
lege Station, TX, USA) was used for the analyses.
Results
The mean age of all 1420 participants was 71.2 years.
The proportion of females was 55%. Out of the partici-
pants, 84% had purchased some prescribed analgesics
during the considered year. All of the prescribed analge-
sics were most frequently obtained by group I subjects,
who reported the most pain, with the percentage de-
creasing linearly with the groups. In group I, 91% of the
participants had picked up the prescribed NSAIDs.
NSAIDs were also largely purchased by those who, at
the moment of the questionnaire data collection, re-
ported no SF-36 bodily pain at all (70%). Forty-one per-
cent of all participants had purchased prescribed
paracetamol. Over half of the participants in group I had
purchased the prescribed opioids, as had almost one
fourth of those with no reported pain at all. In group I,
17% had purchased gabapentinoids and 7% TCAs. Age
(62–66 vs 72–76 vs 82–86 years) did not make a marked
difference in drug distribution or purchasing prevalence.
The analgesic purchases in relation to the four SF-36
bodily pain and according to three age groups are pre-
sented in Table 1.
In total, 32% of the participants had purchased opioids.
Between the opioid and non-opioid group, only a moder-
ate difference was found in SF-36 pain intensity (61 in the
opioid group vs 72 in the non-opioid group) and interfer-
ence (71 vs 82, respectively) (p < 0.001). Cardiovascular,
musculoskeletal, and pulmonary diseases, as well as neo-
plasms, musculoskeletal pain, and depressive symptoms
were more prevalent among opioid users. MetS was
present in 47% of the participants in the opioid group,
compared to the corresponding 40% in the non-opioid
group (p = 0.009). The proportion of those with a BMI of
over 30 was higher in the opioid group (p = 0.049).
Among male participants, waist circumference was slightly
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Number 244 382 478 316
Level 1 analgesics 225 (92) 323 (85) 392 (82) 234 (74) < 0.001
NSAID 200 (91) 303 (80) 375 (78) 222 (70) < 0.001
Paracetamol 151 (62) 185 (48) 162 (34) 85 (27) < 0.001
Level 2–3 analgesics 127 (52) 133 (35) 127 (27) 73 (23) < 0.001
Mild opioid 123 (50) 131 (34) 124 (26) 71 (22) < 0.001
Intermediate/strong opioid 24 (10) 9 (2) 5 (1) 4 (1) < 0.001
Neuropathic pain medication
Gabapentinoid 42 (17) 34 (9) 23 (5) 13 (4) < 0.001
Tricyclic antidepressant 16 (7) 15 (4) 14 (3) 5 (2) < 0.001
AGE 62–66 YEARS
Number 71 163 224 145
Level 1 analgesics 66 (93) 133 (82) 177 (79) 110 (76) < 0.001
NSAID 66 (93) 129 (79) 176 (79) 109 (75) < 0.001
Paracetamol 35 (49) 58 (36) 56 (25) 32 (22) < 0.001
Level 2–3 analgesics 41 (58) 51 (31) 60 (27) 31 (21) < 0.001
Mild opioid 40 (56) 50 (31) 59 (26) 29 (20) < 0.001
Intermediate/strong opioid 4 (6) 2 (1) 2 (1) 2 (1) < 0.001
Neuropathic pain medication
Gabapentinoid 12 (17) 10 (6) 14 (6) 5 (3) < 0.001
Tricyclic antidepressant 7 (10) 7 (4) 9 (4) 0 (0) 0.016
AGE 72–76 YEARS
Number 112 150 197 129
Level 1 analgesics 102 (91) 132 (88) 168 (85) 92 (71) < 0.001
NSAID 99 (88) 123 (82) 158 (80) 86 (67) < 0.001
Paracetamol 75 (67) 83 (55) 79 (40) 33 (26) < 0.001
Level 2–3 analgesics 56 (50) 56 (37) 51 (26) 34 (26) < 0.001
Mild opioid 54 (48) 56 (37) 49 (25) 34 (26) < 0.001
Intermediate/strong opioid 12 (11) 5 (3) 3 (2) 1 (1) < 0.001
Neuropathic pain medication
Gabapentinoid 20 (18) 17 (11) 8 (4) 4 (3) < 0.001
Tricyclic antidepressant 6 (5) 5 (3) 3 (2) 5 (4) 0.023
AGE 82–86 YEARS
Number 61 69 57 42 *
Level 1 analgesics 57 (93) 58 (84) 47 (82) 32 (76) < 0.001
NSAID 56 (92) 54 (78) 41 (72) 27 (64) < 0.001
Paracetamol 41 (67) 44 (64) 27 (47) 20 (48) < 0.001
Level 2–3 analgesics 30 (49) 26 (38) 16 (28) 8 (19) < 0.001
Mild opioid 29 (48) 25 (36) 16 (28) 8 (19) < 0.001
Intermediate/strong opioid 8 (13) 2 (3) 0 (0) 1 (2) < 0.001
Neuropathic pain medication
Gabapentinoid 10 (16) 7 (10) 1 (2) 4 (10) < 0.001
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wider in those who were on opioids. Serum hs-CRP and
uric acid levels were higher among the participants in the
opioid group. Furthermore, 48% of the participants in the
opioid group had visited a doctor more than 3 times dur-
ing the previous 12months, compared to the correspond-
ing 29% in the non-opioid group (p < 0.001). No
differences were found between the groups in terms of co-
habiting, education years, household income, LTPA, waist
circumference in females, alcohol consumption, smoking,
blood pressure, prevalence of diabetes mellitus type II,
psychiatric or neurological disease, headache, insomnia, or
other laboratory measurements. Table 2 illustrates the
characteristics of the groups and all related factors
examined.
According to logistic regression, only pain level and a
higher number of morbidities were found to independ-
ently associate with purchases of Level 1 (NSAIDs and
paracetamol; 1.30 [1.04 to 1.63], p = 0.020) and Level 2–
3 analgesics (opioids; 1.53 [1.30 to 1.79], p < 0.001). No
significant association was found between analgesic pur-
chases and the following variables: sex, age, education
years, smoking, alcohol consumption, LTPA, or MetS
(Table 3).
At the time of the questionnaire data collection, 16%
of the participants in the opioid group reported no SF-
36 pain of any intensity and 30% no SF-36 pain-related
interference. Of all examined variables presented in
Table 4, in addition to morbidities, MetS was the only
factor to independently associate with opioid administra-
tion among these subjects (ORintensity 1.99 [CI 1.10–3.60,
p = 0.022], ORinterference 1.60 [CI1.05–2.43, p = 0.029]).
Discussion
The present population-based study examined prescrip-
tion analgesic purchases among older adults in a modern
Western society. As a major finding, analgesic purchases
were revealed to be substantial. Drug distribution and
purchasing prevalence did not markedly differ between
three age groups (62–66, 72–76 and 82–86 years).
Analgesic purchases
It has been debated whether medical professionals are
lacking in courage when it comes to sufficient pharma-
cological pain treatment in older adults [31, 32]. The re-
sults herein indicate that analgesics are in substantial
use. The prevalence of analgesic purchases was highest
in group I. This was expected, although no temporal
association between the pain assessment and analgesic
purchases was not retrievable. However, analgesics were
also purchased by subjects who, at the time of question-
naire data collection, had reported little or no pain.
The major findings of the current study were the
abundant purchases of NSAIDs and opioids, and the
relatively minor purchases of paracetamol and neuro-
pathic analgesics. The majority of seniors had purchased
at least one prescribed package of NSAIDs during 1 year,
which may be regarded as concerning, considering the
multiple potential contraindications to NSAIDs in older
adults. Surprisingly, paracetamol purchases were in a
clear minority compared to NSAIDs, despite it being
recommended as the drug-of-choice in older adults’ pain
management [6, 7]. Recently, physicians have been en-
couraged to consider not prescribing paracetamol for
patients with lower back pain and osteoarthritis due to
possible inefficacy [33]. It is most likely that a major part
of older adults’ pain is due to musculoskeletal and
chronic inflammatory diseases, for which NSAIDs are ef-
fective [34, 35]. NSAIDs have previously been reported
to be the most prevalent analgesic among robust and
paracetamol among frail and pre-frail community-
dwelling Finnish elderly individuals [18].
On the other hand, the number of those purchasing
analgesics may actually be even higher than what is re-
ported herein, when considering the amount purchased
over the counter [11]. In Finland, small packages of
paracetamol 500 mg and some small-dose NSAIDs (e.g.
ibuprofen) are also available in pharmacies without pre-
scription, but larger packages with a prescription are less
expensive in long-term use. Yet, regarding older adults,
a strong association between increased age and the use
of only prescribed analgesics has been found [36].
Neuropathic drugs were relatively underrepresented,
although the prevalence of neuropathic pain is known to
increase with age [37]. It is possible that a fear of anti-
cholinergic adverse effects and for example risk of falls
and sedation restricted their use. General practitioners
are often responsible for community-dwelling older
adults’ pain management. They may lack expertise in
proper pain assessment and in the use of neuropathic
drugs, in addition to having limited time and resources
and rarely or never an expert pain management team to
refer to. Such a team could most likely be organized
relatively easily at least in larger health care centers, if
this were considered a priority.










Tricyclic antidepressant 3 (5) 3 (4) 2 (4) 0 (0) 0.019
*p for linearity. Groups I–IV: group I [0–45, moderate to very severe pain intensity and interference], group II [47.5–70], group III [77.5–90], group IV [100, no pain
intensity and interference at all]. Three age groups: 62–66, 72–76, 82–86 years
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Bodily Pain, mean (SD) 77 (21) 66 (25) < 0.001*
Intensity, mean (SD) 72 (23) 61 (26) < 0.001*
Interference, mean (SD) 82 (22) 71 (27) < 0.001*
Demographics
Female sex, n (%) 534 (56) 250 (54) 0.65
Age, mean (SD) 71 (7) 72 (7) 0.16
Cohabiting, n (%) 662 (69) 321 (70) 0.75
Education years, mean (SD) 9.8 (3.2) 9.6 (3.1) 0.37
OECDsgrta, mean (SD) 1000€ 1.8 (1.1) 1.7 (0.6) 0.40
Smoking, n (%) 141 (15) 68 (15) 0.97
AUDIT-Cb, mean (SD) 2.6 (2.2) 2.6 (2.2) 0.83
LTPAc, n(%) 0.24
Low 118 (12) 71 (15)
Moderate 689 (72) 323 (71)
High 148 (16) 64 (14)
Clinical
BMId, mean (SD) 27.8 (4.8) 28.4 (4.7) 0.021*
Obese (BMId≥ 30), n (%) 241 (26) 139 (31) 0.049*
Waist cm, mean (SD)
Female 92 (14) 94 (13) 0.057
Male 100 (11) 103 (11) 0.002*
MetSe, n (%) 385 (40) 218 (47) 0.009*
Blood pressure mmHg, mean (SD)
Systolic 138 (21) 137 (19) 0.32
Diastolic 83 (11) 82 (10) 0.10
Morbidity (diagnosed), n (%)
Cardiovascular disease 413 (43) 225 (49) 0.037*
Diabetes mellitus type II 101 (11) 56 (12) 0.35
Musculoskeletal disease 330 (34) 231 (50) < 0.001*
Pulmonary disease 69 (7) 55 (12) 0.003*
Psychiatric disease 27 (3) 22 (5) 0.057
Neurological disease 25 (3) 16 (6) 0.36
Neoplasm 47 (5) 44 (10) < 0.001*
Symptoms, n (%)
Joint pain 264 (28) 182 (40) < 0.001*
Back pain 235 (24) 163 (35) < 0.001*
Neck pain 253 (26) 157 (34) < 0.001*
Headache 109 (11) 61 (13) 0.30
Insomnia 176 (18) 91 (20) 0.51
Depression 40 (4) 32 (7) 0.025*
Laboratory tests, mean (SD)
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Opioid administration
The number of prescription opioid purchases emerged
as extensive. It is known that opioids are widely used,
and the opioid crisis is no longer regarded as a medical,
but rather as a public health crisis [38]. In the USA, the
number of clinical visits where opioids were prescribed
to an older person doubled within a decade (from 1999
to 2000 to 2009–2010) [39]. Pitkälä and colleagues also
came to a similar conclusion in their Finnish follow-up
study [40]. However, large studies evaluating opioid use
among community-dwelling older adults are scarce,
estimating a prevalence of 6–9% [18, 41–44]. The results
of the present study markedly exceeded what has been
reported previously. This may be regarded as a concern-
ing continuation of the previously reported evolution in
opioid prescribing, even though the purchases reported
herein have most likely been for as-needed or short-
term use.
Despite the multiple potential adverse effects, man-
aging pain with opioids may be seen as a tempting
choice from the clinicians’ perspective. Opioids are at
least relatively effective in almost all pain conditions,







Glucose, mMol/L 5.66 (1.05) 5.68 (1.01) 0.72
Triglyceride, mMol/L 1.26 (0.65) 1.23 (0.59) 0.47
HDL, mMol/L 1.58 (0.46) 1.55 (0.47) 0.35
eGFR, mL/min/1.73 cm3 71 (14) 71 (15) 0.89
hsCRP, mg/L 4.2 (4.0) 5.4 (9.5) 0.001*
Uric acid, uMol/L 334 (73) 343 (79) 0.042*
Visited physician ≥3 times, n (%) 282 (29) 223 (48) < 0.001*
*P-values less than 0.05 were considered statistically significant. Data are presented as mean values (SD) and as absolute values and percentages. aOECDsgrt OECD
square root–determined household income; bAUDIT-C Alcohol unit consumption per week; cLTPA Leisure-time physical activity; dBMI Body mass index; eMetS
Metabolic syndrome. Laboratory test abbreviations: HDL High-density lipoprotein, eGFR Estimated glomerular filtration rate, hsCRP High-sensitivity
C-reactive protein
Table 3 Analgesic purchases and associated factors in 1420 GOAL participants. A multivariate logistic regression model
Analgesic purchases
Level 1 analgesics Level 2–3 analgesics
OR (95% CI) p-value OR (95% CI) p-value
Pain levelsa < 0.001* < 0.001*
Group I 1.00 (Reference) 1.00 (Reference)
Group II 0.54 (0.31 to 0.93) 0.56 (0.40 to 0.79)
Group III 0.48 (0.28 to 0.82) 0.41 (0.29 to 0.58)
Group IV 0.30 (0.17 to 0.53) 0.36 (0.24 to 0.53)
Male sex 0.74 (0.53 to 1.01) 0.060 1.13 (0.86 to 1.48) 0.38
Age 1.01 (0.99 to 1.03) 0.45 0.99 (0.97 to 1.01) 0.36
Education years 1.01 (0.97 to 1.06) 0.56 1.01 (0.97 to 1.04) 0.78
Smoking 1.21 (0.78 to 1.86) 0.39 1.03 (0.72 to 1.46) 0.87
AUDIT-Cb 1.00 (0.93 to 1.08) 0.92 1.00 (0.94 to 1.07) 0.99
LTPAc 0.39 0.34
Low 1.00 (Reference) 1.00 (Reference)
Moderate 1.33 (0.88 to 2.00) 0.86 (0.61 to 1.22)
High 1.27 (0.76 to 2.14) 0.80 (0.51 to 1.25)
MetSd 0.91 (0.67 to 1.22) 0.52 1.09 (0.86 to 1.40) 0.47
Number of morbiditiese 1.30 (1.04 to 1.63) 0.020* 1.53 (1.30 to 1.79) < 0.001*
*P-values less than 0.05 were considered statistically significant. Level 1 analgesics: paracetamol, NSAIDs; Level 2–3 analgesics: weak to strong opioids. aPain levels:
Groups I–IV: group I [0–45, moderate to very severe pain intensity and interference], group II [47.5–70], group III [77.5–90], group IV [100, no pain intensity and
interference at all]; bAUDIT-C Alcohol unit consumption per week, cLTPA Leisure-time physical activity, dMetS Metabolic syndrome, eNumber of morbidities sum of
each participant’s diagnosed morbidities
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and they are not absolutely contraindicated for any pa-
tient group. Importantly, the relatively low paracetamol
purchasing percentage may also partially be due to substan-
tial opioid consumption; the majority of purchased opioids
consisted of mild opioids, which is to say (according to the
Finnish practice) a paracetamol-codeine combination or
tramadol. Especially for older adults with possible cognitive
impairments, clinicians may avoid prescribing concomitant
paracetamol and paracetamol-codeine combination due to
a fear of patient-related inadequate dose titration and ex-
ceeding the paracetamol dose limit. It is possible that a con-
comitant NSAID and paracetamol-codeine combination
has been seen as an effective combination in both acute
and chronic pain conditions.
Previously, female sex, poor self-rated health, and the
use of over ten non-analgesic drugs have been found to
associate with any analgesic use, and moderate and poor
self-rated health with opioid use in Finnish community-
dwelling older adults over 75 years of age [45]. Interest-
ingly, therein, opioid and daily analgesic use were inversely
associated with depressive symptoms [45], whereas in an-
other Finnish study by Gilmartin and colleagues, analgesic
use was independently associated with depressive symp-
toms in patients with Alzheimer’s disease [46]. In the
present study, opioid purchases were related to obesity,
metabolic syndrome, and morbidities (e.g. depression),
while there was no difference between the groups in so-
cioeconomic factors or lifestyle, for instance. There was
no trend of purchasing more painkillers among people
with a lower socioeconomic status. Also, opioid purchases,
as well as NSAID and paracetamol purchases, were inde-
pendently associated only with a higher number of mor-
bidities. Opioids were purchased by people who had
musculoskeletal diseases or neoplasms, which are
reasonable causes for the need of opioids. Therefore, the
indication for prescribing an opioid has most likely been
adequate.
MetS was found to independently associate with opioid
purchases in subjects who, at the time of questionnaire
data collection, reported no SF-36 pain of any intensity or
no pain-related interference. Hyperuricemia and an ele-
vated high-sensitivity C-reactive protein level are often
present in MetS [47, 48], and they were both related to
opioid purchasing in the present material. It has been
shown that an individual with diabetes combined with
other MetS components is more likely to have neuropathy
[49], and half of all diabetes patients with neuropathy ex-
perience neuropathic pain [50]. Interestingly, on the mo-
lecular level, severe obesity has recently been found to
associate with decreased u-opioid receptor (MOR) avail-
ability in the brain [51]. The MORs mediate the effects of
both endogenous opioids and exogenous opioid agonists
[52]. Decreased MOR availability is known to lead to di-
minished opioid sensitivity and, further, to opioid toler-
ance [53]. On the other hand, multiple studies have
demonstrated an association between obesity and pain
among older people [54, 55]. Further studies are needed
to specify whether the MetS/obesity–opioid use associ-
ation evolves from the molecular level, or whether obesity
intensifies musculoskeletal symptoms, for example,
thereby leading to a need for opioids. Although the num-
ber and doses of opioids prescribed were not retrievable in
the present study, clinicians should notice that obese se-
niors and those with MetS may be more prone to opioid
use than older adults in general.
The abundant prescribing of opioids—and of all analgesics—
raises the question whether the use of non-pharmacological
methods has been sufficient. Almost half of the participants
Table 4 Associated factors in opioid-purchasing participants with no SF-36 pain. A multivariate logistic regression model
No SF-36 pain intensity
N = 74
No SF-36 pain-related interference
N = 138
OR (95% CI) p-value OR (95% CI) p-value
Male sex 0.88 (0.47 to 1.63) 0.68 1.20 (0.78 to 1.86) 0.40
Age 0.99 (0.94 to 1.03) 0.58 0.97 (0.94 to 1.01) 0.095
Education years 1.01 (0.92 to 1.10) 0.88 1.03 (0.97 to 1.09) 0.37
Smoking 1.71 (0.77 to 3.80) 0.19 1.08 (0.62 to 1.90) 0.78
AUDIT-Ca 0.95 (0.82 to 1.10) 0.47 0.97 (0.88 to 1.08) 0.62
LTPAb 0.99 0.64
Low 1 (Reference) 1 (Reference)
Moderate 0.99 (0.43 to 2.32) 0.92 (0.50 to 1.69)
High 1.00 (0.34 to 2.87) 0.83 (0.39 to 1.79)
MetSc 1.99 (1.10 to 3.60) 0.022* 1.60 (1.05 to 2.43) 0.029*
Number of morbiditiesd 1.84 (1.17 to 2.90) 0.008* 1.50 (1.08 to 2.07) 0.015*
*P-values less than 0.05 were considered statistically significant. aAUDIT-C Alcohol unit consumption per week, bLTPA Leisure-time physical activity, cMetS Metabolic
syndrome, dNumber of morbidities sum of each participant’s diagnosed morbidities. Comparison to subjects that had received opioid prescription and reported
some pain 1) intensity for ‘No pain intensity’ 2) interference for ‘No pain interference’
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who had purchased opioids had visited a doctor frequently, in-
dicating that these individuals should also have been candidates
for non-pharmacological interventions if these had been pro-
vided. The role of primary care physicians may be highlighted
in evaluating the need for non-pharmacological interventions.
Strengths and limitations
A setting with self-reports and clinical data combined
with Kela-provided data regarding analgesic purchases
may be highlighted as the major strength of the present
study. The clinical history in relation to analgesic pur-
chases or the exact number and doses of drugs, nor the
drugs purchased over the counter or the participants’
other medications were not retrievable, which may be
addressed as a limitation. Also, regarding neuropathic
pain, duloxetine and venlafaxine prescriptions were not
retrievable; however, they were possibly not yet widely
used in 2012. In addition, there was a lack of a chrono-
logical association between the pain assessment and an-
algesic purchases. It is possible that the pain was not yet
present at the time of the self-report, or, conversely, ad-
ministered drugs had already relieved the pain, which is
why some participants who had purchased analgesics
had not reported pain. Additionally, the pattern of pre-
scribing has most likely been based on as-needed use,
which has also been reported to be the most common
circumstance in previous studies [23], but we cannot as-
certain this for certain. Furthermore, drug purchases do
not equate with drug use, but investigating the former is
the next-best method of estimating the latter. Finally,
data used herein was over 5 years old which may be seen
as a relative limitation.
Conclusions
Analgesic administration emerged as substantial in the
study, which is comprehensively representative of the
Finnish community-dwelling older population. NSAID
and opioid purchases were revealed to be extensive,
whereas paracetamol and neuropathic analgesics were in
the minority. Age made no marked difference in the
drug distribution and purchasing prevalence. Number of
co-morbidities was the only factor that was independ-
ently associated with analgesic purchases in all subjects,
and metabolic syndrome also with opioid purchases in
subjects who had not reported any bodily pain in the
SF-36. Increasing efforts need to be made regarding re-
sources intended for diminishing inappropriate analgesic
use in older adults. Future studies are needed to evaluate
the consequences (e.g. complications) of extensive use of
analgesics in older adults. The significance of proper
pain assessment, non-pharmacological pain management
(e.g. physical therapy, cognitive behavioral therapy, pain
education) and provider based interventions needs to be
highlighted.
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